444 Federal Register / Vol. 84, No. 19 / Tuesday, January 29, 2019 / Rules and Regulations 

AD is required to be furnished with the 

aircraft, per 14 CFR 25.1581. Further, 

operators of the aircraft affected by this AD 

must operate in accordance with the 

limitations specified in the AFM, per 14 CFR 

91.9. 

(h) Alternative Methods of Compliance 

(AMOCs) 

(1) The Manager, Seattle ACO Branch, 

FAA, has the authority to approve AMOCs 

for this AD, if requested using the procedures 

found in 14 CFR 39.19. In accordance with 

14 CFR 39.19, send your request to your 

principal inspector or local Flight Standards 

District Office, as appropriate. If sending 

information directly to the manager of the 

certification office, send it to the attention of 

the person identified in paragraph (i) of this 

AD. Information may be emailed to: 9-ANMSeattle-ACO-AMOC-Requests@faa.gov. 

(2) Before using any approved AMOC, 

notify your appropriate principal inspector, 

or lacking a principal inspector, the manager 

of the local flight standards district office/ 

certificate holding district office. 

(3) An AMOC that provides an acceptable 

level of safety may be used for any repair, 

modification, or alteration required by this 

AD if it is approved by the Boeing 

Commercial Airplanes Organization 

Designation Authorization (ODA) that has 

been authorized by the Manager, Seattle ACO 

Branch, to make those findings. To be 

approved, the repair method, modification 

deviation, or alteration deviation must meet 

the certification basis of the airplane, and the 

approval must specifically refer to this AD. 

(i) Related Information 

For more information about this AD, 

contact Rebel Nichols, Aerospace Engineer, 

Propulsion Section, FAA, Seattle ACO 

Branch, 2200 South 216th St., Des Moines, 

WA 98198; phone and fax: 206–231–3556; 

email: Rebel.Nichols@faa.gov. 

(j) Material Incorporated by Reference 

None. 

Issued in Des Moines, Washington, on 

January 23, 2019. 

Jeffrey E. Duven, 

Director, System Oversight Division, Aircraft 

Certification Service. 

[FR Doc. 2019–00297 Filed 1–28–19; 8:45 am] 

BILLING CODE 4910–13–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

21 CFR Part 1308 

[Docket No. DEA–421] 

Schedules of Controlled Substances: 

Placement of MAB-CHMINACA in 

Schedule I 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Final rule. 

SUMMARY: The Drug Enforcement 

Administration places N-(1-amino-3,3- 

dimethyl-1-oxobutan-2-yl)-1- 

(cyclohexylmethyl)-1H-indazole-3- 

carboxamide (MAB-CHMINACA; ADBCHMINACA), including its salts, 

isomers, and salts of isomers whenever 

the existence of such salts, isomers, and 

salts of isomers is possible, in schedule 

I of the Controlled Substances Act. This 

action continues the imposition of the 

regulatory controls and administrative, 

civil, and criminal sanctions applicable 

to schedule I controlled substances on 


ER29JA19.000</GPH>
Federal Register / Vol. 84, No. 19 / Tuesday, January 29, 2019 / Rules and Regulations 445 

1As set forth in a memorandum of understanding 

entered into by the Food and Drug Administration 

(FDA) and the National Institute on Drug Abuse 

(NIDA), the FDA acts as the lead agency within the 

Department of Health and Human Services (HHS) 

in carrying out the Secretary’s scheduling 

responsibilities under the CSA, with the 

concurrence of NIDA. 50 FR 9518, Mar. 8, 1985. 

The Secretary of the HHS has delegated to the 

Assistant Secretary for Health of the HHS the 

authority to make domestic drug scheduling 

recommendations. 58 FR 35460, July 1, 1993. 

persons who handle (manufacture, 

distribute, import, export, engage in 

research, conduct instructional 

activities or chemical analysis, or 

possess), or propose to handle MABCHMINACA. 

DATES: Effective January 29, 2019. 

FOR FURTHER INFORMATION CONTACT: 

Regulatory Drafting and Policy Section, 

Diversion Control Division, Drug 

Enforcement Administration; Mailing 

Address: 8701 Morrissette Drive, 

Springfield, Virginia 22152; Telephone: 

(202) 598–8953. 

SUPPLEMENTARY INFORMATION: 

Legal Authority 

Under the Controlled Substances Act 

(CSA), each controlled substance is 

classified into one of five schedules 

based upon its potential for abuse, its 

currently accepted medical use, and the 

degree of dependence the substance 

may cause. 21 U.S.C. 812. The initial 

schedules of controlled substances 

established by Congress are found at 21 

U.S.C. 812(c), and the current list of 

scheduled substances is published at 21 

CFR part 1308. 

Pursuant to 21 U.S.C. 811(a)(1), the 

Attorney General may, by rule, ‘‘add to 

such a schedule or transfer between 

such schedules any drug or other 

substance if he (A) finds that such drug 

or other substance has a potential for 

abuse, and (B) makes with respect to 

such drug or other substance the 

findings prescribed by subsection (b) of 

section 812 of this title for the schedule 

in which such drug is to be placed. 

. . . ’’ The Attorney General has 

delegated scheduling authority under 21 

U.S.C. 811 to the Administrator of the 

DEA (Administrator). 28 CFR 0.100. 

The CSA provides that proceedings 

for the issuance, amendment, or repeal 

of the scheduling of any drug or other 

substance may be initiated by the 

Attorney General (1) on his own motion; 

(2) at the request of the Secretary of the 

Department of Health and Human 

Services (HHS); 1 or (3) on the petition 

of any interested party. 21 U.S.C. 811(a). 

This action was initiated on the 

Attorney General’s own motion, as 

delegated to the Administrator, and is 

supported by, inter alia, a 

recommendation from the Acting 

Assistant Secretary for Health of the 

HHS (Acting Assistant Secretary) and an 

evaluation of all relevant data by the 

DEA. This action continues the 

imposition of the regulatory controls 

and administrative, civil, and criminal 

sanctions of schedule I controlled 

substances on any person who handles 

or proposes to handle MABCHMINACA. 

Background 

On February 5, 2016, the DEA 

published a final order in the Federal 

Register amending 21 CFR 1308.11(h) to 

temporarily place the synthetic 

cannabinoid N-(1-amino-3,3-dimethyl-1- 

oxobutan-2-yl)-1-(cyclohexylmethyl)- 

1H-indazole-3-carboxamide (other 

names: MAB-CHMINACA; ADBCHMINACA) in schedule I of the CSA 

pursuant to the temporary scheduling 

provisions of 21 U.S.C. 811(h). 81 FR 

6171. That final order was effective on 

the date of publication, and was based 

on findings by the Acting Administrator 

of the DEA (Acting Administrator) that 

the temporary scheduling of this 

synthetic cannabinoid was necessary to 

avoid an imminent hazard to the public 

safety pursuant to 21 U.S.C. 811(h)(1). 

Section 201(h)(2) of the CSA, 21 U.S.C. 

811(h)(2), requires that the temporary 

control of this substance expire two 

years from the issuance date of the 

scheduling order, on or before February 

4, 2018. However, the CSA also 

provides that during the pendency of 

proceedings under 21 U.S.C. 811(a)(1), 

with respect to the substance, the 

temporary scheduling of that substance 

could be extended for up to one year. 

Accordingly, on January 30, 2018, the 

DEA extended the temporary scheduling 

of MAB-CHMINACA by one year, or 

until February 5, 2019. 83 FR 4411. 

Also, on January 30, 2018, the DEA 

published a notice of proposed 

rulemaking (NPRM) to permanently 

control MAB-CHMINACA in schedule I 

of the CSA. 83 FR 4406. Specifically, the 

DEA proposed to add this synthetic 

cannabinoid to the hallucinogenic 

substances list under 21 CFR 

1308.11(d). 

DEA and HHS Eight Factor Analyses 

On January 19, 2018, the HHS 

provided the DEA with a scientific and 

medical evaluation document prepared 

by the Food and Drug Administration 

(FDA) entitled ‘‘Basis for the 

Recommendation to Place N-(1-amino3,3-dimethyl-1-oxobutan-2-yl)-1- 

(cyclohexylmethyl)-1H-indazole-3- 

carboxamide (MAB-CHMINACA; ADBCHMINACA), and its salts, in Schedule 

I of the Controlled Substances Act.’’ 

After considering the eight factors in 21 

U.S.C. 811(c), each substance’s abuse 

potential, lack of legitimate medical use 

in the United States, and lack of 

accepted safety for use under medical 

supervision pursuant to 21 U.S.C. 

812(b), the Acting Assistant Secretary 

recommended that MAB-CHMINACA be 

controlled in schedule I of the CSA. In 

response, the DEA conducted its own 

eightfactor analysis of MABCHMINACA. The DEA and HHS 

analyses are available in their entirety in 

the public docket for this rule (Docket 

Number DEA–421/DEA–2018–0001) at 

http://www.regulations.gov under 

‘‘Supporting Documents.’’ 

Determination to Schedule MABCHMINACA 

After a review of the available data, 

including the scientific and medical 

evaluation, and the scheduling 

recommendations from the HHS, the 

DEA published an NPRM entitled 

‘‘Schedules of Controlled Substances: 

Placement of MAB-CHMINACA into 

Schedule I.’’ This NPRM proposed to 

control MAB-CHMINACA, and its salts, 

isomers, and salts of isomers in 

schedule I of the CSA. 83 FR 4406, 

January 30, 2018. The proposed rule 

provided an opportunity for interested 

persons to file a request for hearing in 

accordance with the DEA regulations on 

or before March 1, 2018. No requests for 

such a hearing were received by the 

DEA. The NPRM also provided an 

opportunity for interested persons to 

submit written comments on the 

proposed rule on or before March 1, 

2018. 

Comments Received 

The DEA received six comments on 

the proposed rule to control MABCHMINACA in schedule I of the CSA. 

Not related to rulemaking: Four 

commenters submitted responses that 

did not pertain to the rulemaking and 

were not considered. 

DEA’s Future Diversion Efforts: One 

commenter quoted various statements 

from the proposed rule pertaining to the 

risk of MAB-CHMINACA to the public 

health (i.e., information about clusters 

of overdoses, deaths, and adverse health 

effects associated with these incidents) 

and questioned the DEA’s future 

response to stay ahead of synthetic 

cannabinoid manufacturers who alter 

the chemical formulation of substances 

to circumvent current controls. 

DEA Response: The DEA continues to 

monitor various synthetic cannabinoids 

and has taken additional control actions 

against new substances as they are 

encountered. The DEA is continuing to 

use all available resources to address the 

446 Federal Register / Vol. 84, No. 19 / Tuesday, January 29, 2019 / Rules and Regulations 

2MAB-CHMINACA is currently subject to 

schedule I controls on a temporary basis, pursuant 

to 21 U.S.C. 811(h). 81 FR 6171, Feb. 5, 2016. 

issue of trafficking and abuse of novel 

psychoactive substances to safeguard 

the public from hazards associated with 

these substances. 

Dissent for rulemaking: One 

commenter acknowledged that MABCHMINACA has no currently accepted 

medical use in treatment and there is a 

lack of accepted safety for its use under 

medical supervision. However, the 

commenter believes this does not 

represent the danger or high abuse 

potential of the substance, attributed to 

it by DEA. Rather, the commenter 

believes MAB-CHMINACA is so similar 

to tetrahydrocannabinol (THC) that its 

use is ‘‘a symptom of’’ the schedule I 

controls placed on THC, and questions 

the reliability of the data that DEA 

provided—as reported by state public 

health entities over a two-month period 

in 2015—to support Factor 4 (Its History 

and Current Pattern of Abuse). The 

commenter predicted that use of this 

drug has likely dropped since 2015 due 

to ‘‘medicinal THC use’’ becoming more 

acceptable by the general public 

nationwide, and therefore does not 

reflect the current abuse potential. 

Additionally, this commenter expressed 

concern that placing MAB-CHMINACA 

in schedule I would prevent medical 

research. 

DEA Response: The DEA does not 

agree. Both the DEA and HHS analyses 

documented serious adverse effects 

including the deaths of individuals 

following the ingestion of MABCHMINACA. Pharmacology studies, 

overdose reports, law enforcement 

seizures, and other data collectively 

demonstrated the hazard to public 

safety and the dangers associated with 

this substance. With regard to the 

commenter’s prediction that abuse of 

MAB-CHMINACA will become 

secondary due to the notion that THC is 

becoming more widely accepted, it is 

important to note that the extent of 

trafficking and abuse of a given 

substance at a given time is not typically 

determined by a sole factor. Complex 

factors related to the substance’s abuse 

potential, market dynamics such as 

availability of similar other novel 

substances, and drug use trends in the 

drug abuser community are also 

considered when scheduling a 

substance. In fact, following temporary 

control of MAB-CHMINACA, several 

pharmacologically similar new 

substances appeared on the illicit 

market and the DEA has taken control 

actions on these substances. While 

MAB-CHMINACA continues to be 

abused in the United States, law 

enforcement encounters have decreased, 

as normally occur following the control 

of synthetic cannabinoids, including 

MAB-CHMINACA. As with other 

dangerous substances, the placement of 

a drug in schedule I does require 

additional regulatory controls. The 

Diversion Control Division’s mission is 

to prevent, detect and investigate the 

diversion of controlled substances while 

ensuring an adequate and uninterrupted 

supply of these substances to meet 

legitimate medical, commercial and 

scientific needs. The DEA ensures that 

adequate security measures and 

background investigations are 

conducted for researchers who have 

legitimate need to conduct research and 

development with schedule I controlled 

synthetic drug substances. 

Scheduling Conclusion 

After consideration of the relevant 

matter presented as a result of public 

comments, the scientific and medical 

evaluations and accompanying 

recommendation of HHS, and after its 

own eight-factor evaluation, the DEA 

finds that these facts and all other 

relevant data constitute substantial 

evidence of potential for abuse of MABCHMINACA. As such, the DEA is 

permanently scheduling MABCHMINACA as a controlled substance 

under the CSA. 

Determination of Appropriate Schedule 

The CSA establishes five schedules of 

controlled substances known as 

schedules I, II, III, IV, and V. The CSA 

also outlines the findings required to 

place a drug or other substance in any 

particular schedule. 21 U.S.C. 812(b). 

After consideration of the analyses and 

recommendations of the Assistant 

Secretary and review of all other 

available data, the Acting 

Administrator, pursuant to 21 U.S.C. 

811(a) and 812(b)(1), finds that: 

(1) N-(1-amino-3,3-dimethyl-1- 

oxobutan-2-yl)-1-(cyclohexylmethyl)- 

1H-indazole-3-carboxamide (MABCHMINACA; ADB-CHMINACA) has a 

high potential for abuse that is 

comparable to other schedule I 

substances such as delta-9- 

tetrahydrocannabinol (D9-THC) and 

JWH–018; 

(2) N-(1-amino-3,3-dimethyl-1- 

oxobutan-2-yl)-1-(cyclohexylmethyl)- 

1H-indazole-3-carboxamide (MABCHMINACA; ADB-CHMINACA) has no 

currently accepted medical use in 

treatment in the United States; and 

(3) There is a lack of accepted safety 

for use of N-(1-amino-3,3-dimethyl-1- 

oxobutan-2-yl)-1-(cyclohexylmethyl)- 

1H-indazole-3-carboxamide (MABCHMINACA; ADB-CHMINACA) under 

medical supervision. 

Based on these findings, the Acting 

Administrator concludes that N-(1- 

amino-3,3-dimethyl-1-oxobutan-2-yl)-1- 

(cyclohexylmethyl)-1H-indazole-3- 

carboxamide (MAB-CHMINACA; ADBCHMINACA), including its salts, 

isomers and salts of isomers, whenever 

the existence of such salts, isomers, and 

salts of isomers is possible, warrants 

control in schedule I of the CSA. 21 

U.S.C. 812(b)(1). 

Requirements for Handling MABCHMINACA 

MAB-CHMINACA will continue 2 to 

be subject to the CSA’s schedule I 

regulatory controls and administrative, 

civil, and criminal sanctions applicable 

to the manufacture, distribution, 

dispensing, importing, exporting, 

research, and conduct of instructional 

activities, including the following: 

1. Registration. Any person who 

handles (manufactures, distributes, 

imports, exports, engages in research, or 

conducts instructional activities or 

chemical analysis with, or possesses), or 

who desires to handle, MABCHMINACA must be registered with the 

DEA to conduct such activities pursuant 

to 21 U.S.C. 822, 823, 957, and 958 and 

in accordance with 21 CFR parts 1301 

and 1312. 

2. Security. MAB-CHMINACA is 

subject to schedule I security 

requirements and must be handled and 

stored pursuant to 21 U.S.C. 821, 823, 

871(b) and in accordance with 21 CFR 

1301.71–1301.93. 

3. Labeling and Packaging. All labels 

and labeling for commercial containers 

of MAB-CHMINACA must be in 

compliance with 21 U.S.C. 825 and 

958(e), and be in accordance with 21 

CFR part 1302. 

4. Quota. Only registered 

manufacturers are permitted to 

manufacture MAB-CHMINACA in 

accordance with a quota assigned 

pursuant to 21 U.S.C. 826 and in 

accordance with 21 CFR part 1303. 

5. Inventory. Every DEA registrant 

who possesses any quantity of MABCHMINACA on the effective date of this 

final rule, must take an inventory of all 

stocks of these substances on hand as of 

January 29, 2019, pursuant to 21 U.S.C. 

827 and 958 and in accordance with 21 

CFR 1304.03, 1304.04, and 1304.11 (a) 

and (d). Current DEA registrants shall 

have 30 calendar days from the effective 

date of this order to be in compliance 

with all inventory requirements. 

After the initial inventory, every DEA 

registrant must take a new inventory of 

all controlled substances (including 

MAB-CHMINACA) on hand on a 

Federal Register / Vol. 84, No. 19 / Tuesday, January 29, 2019 / Rules and Regulations 447 

biennial basis, pursuant to 21 U.S.C. 827 

and 958, and in accordance with 21 CFR 

1304.03, 1304.04, and 1304.11. 

6. Records and Reports. Every DEA 

registrant must maintain records and 

submit reports with respect to MABCHMINACA pursuant to 21 U.S.C. 827 

and 958(e), and in accordance with 21 

CFR parts 1304 and 1312. 

7. Order Forms. Every DEA registrant 

who distributes MAB-CHMINACA must 

continue to comply with the order form 

requirements, pursuant to 21 U.S.C. 828, 

and 21 CFR part 1305. 

8. Importation and Exportation. All 

importation and exportation of MABCHMINACA must continue to be in 

compliance with 21 U.S.C. 952, 953, 

957, and 958, and in accordance with 21 

CFR part 1312. 

9. Liability. Any activity involving 

MAB-CHMINACA not authorized by, or 

in violation of, the CSA or its 

implementing regulations is unlawful, 

and may subject the person to 

administrative, civil, and/or criminal 

sanctions. 

Regulatory Analyses 

Executive Orders 12866, 13563, and 

13771, Regulatory Planning and Review, 

Improving Regulation and Regulatory 

Review, and Reducing Regulation and 

Controlling Regulatory Costs 

In accordance with 21 U.S.C. 811(a), 

this scheduling action is subject to 

formal rulemaking procedures done ‘‘on 

the record after opportunity for a 

hearing,’’ which are conducted pursuant 

to the provisions of 5 U.S.C. 556 and 

557. The CSA sets forth the criteria for 

scheduling a drug or other substance. 

Such actions are exempt from review by 

the Office of Management and Budget 

(OMB) pursuant to section 3(d)(1) of 

Executive Order 12866 and the 

principles reaffirmed in Executive Order 

13563. 

This final rule does not meet the 

definition of an Executive Order 13771 

regulatory action. OMB has previously 

determined that formal rulemaking 

actions concerning the scheduling of 

controlled substances, such as this rule, 

are not significant regulatory actions 

under Section 3(f) of Executive Order 

12866. 

Executive Order 12988 

This regulation meets the applicable 

standards set forth in sections 3(a) and 

3(b)(2) of Executive Order 12988 to 

eliminate drafting errors and ambiguity, 

minimize litigation, provide a clear legal 

standard for affected conduct, and 

promote simplification and burden 

reduction. 

Executive Order 13132 

This rulemaking does not have 

federalism implications warranting the 

application of Executive Order 13132. 

The rule does not have substantial 

direct effects on the States, on the 

relationship between the national 

government and the States, or the 

distribution of power and 

responsibilities among the various 

levels of government. 

Executive Order 13175 

This rule does not have tribal 

implications warranting the application 

of Executive Order 13175. It does not 

have substantial direct effects on one or 

more Indian tribes, on the relationship 

between the Federal government and 

Indian tribes, or on the distribution of 

power and responsibilities between the 

Federal government and Indian tribes. 

Regulatory Flexibility Act 

The Acting Administrator, in 

accordance with the Regulatory 

Flexibility Act, 5 U.S.C. 601–602, has 

reviewed this final rule and by 

approving it certifies that it will not 

have a significant economic impact on 

a substantial number of small entities. 

On February 6, 2016, the DEA published 

a final order to temporarily place this 

substance in schedule I of the CSA 

pursuant to the temporary scheduling 

provisions of 21 U.S.C. 811(h). The DEA 

estimates that all entities handling or 

planning to handle these substances 

have already established and 

implemented the systems and processes 

required to handle MAB-CHMINACA. 

As of January 2018, there were 16 

registrations authorized to handle MABCHMINACA specifically, as well as a 

number of registered analytical labs that 

are authorized to handle schedule I 

controlled substances generally. These 

16 registrations represent 14 entities, of 

which 8 are small entities. Therefore, 

the DEA estimates eight small entities 

are affected by this rule. 

A review of the 16 registrations 

indicates that all entities that currently 

handle MAB-CHMINACA also handle 

other schedule I controlled substances, 

and have established and implemented 

(or maintain) the systems and processes 

required to handle MAB-CHMINACA. 

Therefore, the DEA anticipates that this 

rule will impose minimal or no 

economic impact on any affected 

entities; and thus, will not have a 

significant economic impact on any of 

the eight affected small entities. 

Therefore, the DEA has concluded that 

this rule will not have a significant 

effect on a substantial number of small 

entities. 

Unfunded Mandates Reform Act of 1995 

In accordance with the Unfunded 

Mandates Reform Act (UMRA) of 1995, 

2 U.S.C. 1501 et seq., the DEA has 

determined and certifies that this action 

would not result in any Federal 

mandate that may result ‘‘in the 

expenditure by State, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $100,000,000 or more 

(adjusted for inflation) in any one year 

* * *.’’ Therefore, neither a Small 

Government Agency Plan nor any other 

action is required under UMRA of 1995. 

Paperwork Reduction Act of 1995 

This action does not impose a new 

collection of information under the 

Paperwork Reduction Act of 1995. 44 

U.S.C. 3501–3521. This action would 

not impose recordkeeping or reporting 

requirements on State or local 

governments, individuals, businesses, or 

organizations. An agency may not 

conduct or sponsor, and a person is not 

required to respond to, a collection of 

information unless it displays a 

currently valid OMB control number. 

Congressional Review Act 

This rule is not a major rule as 

defined by the Congressional Review 

Act (CRA), 5 U.S.C. 804. This rule will 

not result in: ‘‘an annual effect on the 

economy of $100,000,000 or more; a 

major increase in costs or prices for 

consumers, individual industries, 

Federal, State, or local government 

agencies, or geographic regions; or 

significant adverse effects on 

competition, employment, investment, 

productivity, innovation, or on the 

ability of United States-based 

enterprises to compete with foreignbased enterprises in domestic and 

export markets.’’ However, pursuant to 

the CRA, the DEA has submitted a copy 

of this final rule to both Houses of 

Congress and to the Comptroller 

General. 

List of Subjects in 21 CFR Part 1308 

Administrative practice and 

procedure, Drug traffic control, 

Reporting and recordkeeping 

requirements. 

For the reasons set out above, 21 CFR 

part 1308 is amended as follows: 

PART 1308—SCHEDULES OF 

CONTROLLED SUBSTANCES 

■ 1. The authority citation for 21 CFR 

part 1308 continues to read as follows: 

Authority: 21 U.S.C. 811, 812, 871(b), 

956(b) unless otherwise noted. 

448 Federal Register / Vol. 84, No. 19 / Tuesday, January 29, 2019 / Rules and Regulations 

■ 2. In § 1308.11, add paragraph (d)(72) 

and remove and reserve paragraph 

(h)(1). 

The addition to read as follows: 

§ 1308.11 Schedule I. 

* * * * * 

(d) * * * 

(72) N-(1-amino-3,3-dimethyl-1- 

oxobutan-2-yl)-1-(cyclohexylmethyl)- 

1H-indazole-3-carboxamide (MABCHMINACA; ADBCHMINACA)....................(7032) 

* * * * * 

Dated: January 18, 2019. 

Uttam Dhillon, 

Acting Administrator. 

[FR Doc. 2019–00254 Filed 1–28–19; 8:45 am] 

BILLING CODE 4410–09–P